An impressive response to pazopanib in a patient with metastatic endometrial carcinoma

M. J. Van Der Steen, Y. R.P. De Waal, A. Westermann, B. Tops, W. Leenders, P. B. Ottevanger

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.

Original languageEnglish
Pages (from-to)410-413
Number of pages4
JournalNetherlands Journal of Medicine
Volume74
Issue number9
Publication statusPublished - Nov 2016
Externally publishedYes

Keywords

  • Complete remission
  • Endometrial cancer
  • Endometrial carcinoma
  • Pazopanib
  • Tyrosine kinase inhibitor

Fingerprint

Dive into the research topics of 'An impressive response to pazopanib in a patient with metastatic endometrial carcinoma'. Together they form a unique fingerprint.

Cite this